+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The efficacy and safety of sulindac 400 mg vs 600 mg daily in rheumatoid arthritis a canadian multicenter study



The efficacy and safety of sulindac 400 mg vs 600 mg daily in rheumatoid arthritis a canadian multicenter study



Journal of Rheumatology 15(6): 1001-1004



Sulindac, an indene derivative of indomethacin, was compared at 2 dosages (400 mg and 600 mg daily) in patients with rheumatoid arthritis. One hundred sixty-two patients from 19 centers completed the study.sbd.85 in the low dose group and 77 in the high dose. No difference in efficacy was found between these 2 regimens. Overall adverse reactions were more frequent with the high dose group especially with respect to blood chemistry and gastrointestinal reactions.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 006669465

Download citation: RISBibTeXText

PMID: 3047380


Related references

A double blind multicenter study of sulindac once daily versus sulindac twice daily in rheumatoid arthritis. Current Therapeutic Research 41(5): 679-691, 1987

Multicenter double blind study of the efficacy safety and tolerance of pirazolac compared with sulindac in patients with rheumatoid arthritis. Drugs under Experimental & Clinical Research 16(1): 17-28, 1990

A double blind multicenter study of sulindac once daily versus sulindac twice daily in osteoarthritis of the knee. Current Therapeutic Research 41(5): 692-705, 1987

Efficacy and safety of OM-8980 in patients with rheumatoid arthritis: An open-label, long-term, multicenter study. Current Therapeutic Research 60(12): 638-649, 1999

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clinical Rheumatology 28(2): 129-137, 2009

Long-term multicenter, open label comparative study of sulindac and indomethacin in rheumatoid arthritis. Ryumachi 22(2): 168-184, 1982

A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. British Journal of Rheumatology 35(Suppl. 1): 22-28, 1996

Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study. Journal of Rheumatology 38(9): 1875-1883, 2011

A multicenter open-label phase I/II study to assess the safety, tolerability, and efficacy of three dose levels of TuNEX in patients with rheumatoid arthritis. Journal of the Chinese Medical Association 74(12): 544-551, 2011

Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Modern Rheumatology 17(1): 1-9, 2007

RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database. Modern Rheumatology 26(3): 336-341, 2016

Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry. Arthritis Care and Research 66(8): 1142-1151, 2014

A multicenter trial of sulindac in rheumatoid arthritis. Ryumachi 19(2): 164-182, 1979